New bone marrow transplant program opens in Arizona
Good news for hematologic cancer patients in need of a hematopoietic stem cell transplant living in the southwestern United States.
The Virginia G. Piper Cancer Center at Scottsdale Healthcare recently announced the addition of a hematopoietic stem cell transplant cancer treatment program at the facility's new Cancer Transplant Institute.
The program is expected to attract hematologic cancer patients including those with lymphomas in desperate need of a bone marrow transplant.
Already a member of the National Marrow Transplant Program (NMDP), which allows it to perform unrelated donor transplants, the Cancer Transplant Institute at the Virginia G. Piper Cancer Center is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) for autologous and allogeneic adult transplants.
Source: PR Newswire
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
